Retrieve available abstracts of 76 articles: HTML format
Single Articles
June 2025
BERTRAN M, Abdullahi F, D'Aeth JC, Amin-Chowdhury Z, et al Recurrent invasive pneumococcal disease in children: A retrospective cohort
study, England, 2006/07-2017/18.
J Infect. 2025;90:106490. PubMedAbstract available
May 2025
OLIVEIRA LVN, Hargarten JC, Wang R, Carlson D, et al Peripheral blood CD4(+) and CD8(+) T cell responses to Cryptococcus candidate
vaccine antigens in human subjects with and without cryptococcosis.
J Infect. 2025;91:106521. PubMedAbstract available
RIEDMANN U, Chalupka A, Richter L, Werber D, et al Corrigendum to "Underlying health biases in previously-infected SARS-CoV-2
vaccination recipients: A cohort study" [J Infect 90 (2025) 106497].
J Infect. 2025;91:106522. PubMed
CHACON GP, McAlister S, Totterdell J, Estcourt MJ, et al Immune impacts of infant whole-cell and acellular pertussis vaccination on
co-administered vaccines.
J Infect. 2025 May 23:106515. doi: 10.1016/j.jinf.2025.106515. PubMedAbstract available
April 2025
RIEDMANN U, Chalupka A, Richter L, Werber D, et al Underlying health biases in previously-infected SARS-CoV-2 vaccination
recipients: a cohort study.
J Infect. 2025 Apr 30:106497. doi: 10.1016/j.jinf.2025.106497. PubMedAbstract available
SEPPANEN EJ, Bayliss J, Clark SL, Gamez C, et al Haemophilus influenzae remains the predominant otitis media pathogen in
Australian children undergoing ventilation tube insertion in the PCV13 era.
J Infect. 2025;90:106478. PubMedAbstract available
March 2025
PEREZ CM, Ruiz-Rius S, Ramirez-Morros A, Vidal M, et al Post-vaccination IgG4 and IgG2 class switch associates with increased risk of
SARS-CoV-2 infections.
J Infect. 2025 Mar 18:106473. doi: 10.1016/j.jinf.2025.106473. PubMedAbstract available
WARD T, Paton RS, Overton CE, Mellor J, et al Understanding the Effectiveness of the Comirnaty Monovalent and Bivalent Vaccines
During the Winter Coronavirus (COVID-19) Infection Survey.
J Infect. 2025 Mar 5:106461. doi: 10.1016/j.jinf.2025.106461. PubMedAbstract available
February 2025
MAZARAKIS N, Toh ZQ, Neal E, Bright K, et al The immunogenicity, reactogenicity, and safety of a bivalent mRNA or protein
COVID-19 vaccine given as a fourth dose.
J Infect. 2025 Feb 18:106447. doi: 10.1016/j.jinf.2025.106447. PubMedAbstract available
WILLIAMS KV, Krauland MG, Nowalk MP, Harrison LH, et al Increasing child vaccination coverage can reduce influenza cases across age
groups: An agent-based modeling study.
J Infect. 2025;90:106443. PubMedAbstract available
NOBLE C, McDonald E, Nicholson S, Biering-Sorensen S, et al Characterising the SARS-CoV-2 nucleocapsid (N) protein antibody response.
J Infect. 2025 Feb 6:106436. doi: 10.1016/j.jinf.2025.106436. PubMedAbstract available
ZIMAKOFF AC, Jensen A, Malon M, Sorensen JK, et al Measles-mumps-rubella vaccination at 6 months of age and the risk of atopic
disease in the first year of life: Results from a Danish placebo-controlled
randomised trial.
J Infect. 2025 Feb 2:106433. doi: 10.1016/j.jinf.2025.106433. PubMedAbstract available
January 2025
BENNETT C, Chau G, Clayton E, Chu L, et al Safety and Immunogenicity of Omicron Protein Vaccines in mRNA-Vaccinated
Adolescents: A Phase 3, Randomised Trial.
J Infect. 2025 Jan 26:106428. doi: 10.1016/j.jinf.2025.106428. PubMedAbstract available
YANG Y, Knoll MD, Herbert C, Bennett JC, et al Global impact of 10- and 13-valent pneumococcal conjugate vaccines on
pneumococcal meningitis in all ages: the PSERENADE project.
J Infect. 2025 Jan 24:106426. doi: 10.1016/j.jinf.2025.106426. PubMedAbstract available
SILVA SOUZA M, Pires Farias J, de Souza Ferreira LC, Amorim JH, et al Declining COVID-19 vaccination coverage in Brazil: A global health warning.
J Infect. 2025;90:106418. PubMed
ZHANG S, Liu J Optimization of Diphtheria, Tetanus and Pertussis (DTP) vaccination strategy in
China.
J Infect. 2025;90:106416. PubMed
FENG S, Bibi S, Aley PK, Cappuccini F, et al Safety and humoral immunogenicity of the ChAdOx1 nCoV-19 vaccine administered as
a fourth dose booster following two doses of ChAdOx1 nCoV-19 and a third dose of
BNT162b2 (COV009): A prospective cohort study.
J Infect. 2025;90:106423. PubMedAbstract available
RJOOB K, Antonelli M, Murray B, Molteni E, et al Symptom Evolution in Individuals with Ongoing Symptomatic COVID-19 and Post
COVID-19 Syndrome After SARS-CoV-2 Vaccination Versus Influenza Vaccination.
J Infect. 2025 Jan 10:106406. doi: 10.1016/j.jinf.2024.106406. PubMedAbstract available
GEHRT L, Moller S, Englund H, Laake I, et al Vaccination against measles-mumps-rubella and rates of non-targeted infectious
disease hospitalisations: Nationwide register-based cohort studies in Denmark,
Finland, Norway, and Sweden.
J Infect. 2025 Jan 7:106365. doi: 10.1016/j.jinf.2024.106365. PubMedAbstract available
ONG DS, Harris M, Hart JD, Russell FM, et al Lack of correlation between school reopening and trends in adult COVID-19
hospitalisations and death rates during the Delta and early Omicron periods: an
ecological analysis of five countries.
J Infect. 2025 Jan 6:106390. doi: 10.1016/j.jinf.2024.106390. PubMedAbstract available
JORDA A, Prager M, Pracher L, Haselwanter P, et al Immunogenicity, Safety, and Reactogenicity of Concomitant Administration of the
Novavax Vaccine against Omicron XBB.1.5 (NVX-CoV2601) and a 20-valent
Pneumococcal Conjugate Vaccine in Adults Aged >/=60 Years: A Randomised,
Double-blind, Placebo-contro
J Infect. 2025 Jan 3:106405. doi: 10.1016/j.jinf.2024.106405. PubMedAbstract available
December 2024
YANG Y, Shen X, Hu H, Wang Y, et al The need for inclusion of the Hib vaccine in mainland national immunization
program in China.
J Infect. 2024 Dec 23:106386. doi: 10.1016/j.jinf.2024.106386. PubMed
MOK CKP, Tang YS, Tan CW, Chong KC, et al Comparison of safety and immunogenicity in the elderly after receiving either
Comirnaty or Spikevax monovalent XBB1.5 COVID-19 vaccine.
J Infect. 2024;90:106374. PubMedAbstract available
BORROW R, Campbell H, Caugant DA, Cherkaoui A, et al Global Meningococcal Initiative: Insights on antibiotic resistance, control
strategies and advocacy efforts in Western Europe.
J Infect. 2024;89:106335. PubMedAbstract available
November 2024
JIA T, Wang F, Chen Y, Liao G, et al Expanded immune imprinting and neutralization spectrum by hybrid immunization
following breakthrough infections with SARS-CoV-2 variants after three-dose
vaccination.
J Infect. 2024 Nov 26:106362. doi: 10.1016/j.jinf.2024.106362. PubMedAbstract available
CHOW KN, Tsang YW, Chan YH, Telaga SA, et al The effect of pre-COVID and post-COVID vaccination on long COVID: a systematic
review and meta-analysis.
J Infect. 2024 Nov 21:106358. doi: 10.1016/j.jinf.2024.106358. PubMedAbstract available
MCLEOD C, Dymock M, Flanagan KL, Plebanski M, et al The Platform Trial In COVID-19 priming and BOOsting (PICOBOO): the
immunogenicity, reactogenicity, and safety of licensed COVID-19 vaccinations
administered as a second booster in BNT162b2 primed individuals aged 18-<50 and
50-<70 years old.
J Infect. 2024 Nov 14:106346. doi: 10.1016/j.jinf.2024.106346. PubMedAbstract available
MAHTAB S, Madewell ZJ, Baillie V, Dangor Z, et al Etiologies and Comorbidities of Meningitis Deaths in Children Under 5 Years in
High-Mortality Settings: Insights from the CHAMPS Network in the
Post-Pneumococcal Vaccine Era.
J Infect. 2024 Nov 7:106341. doi: 10.1016/j.jinf.2024.106341. PubMedAbstract available
DULFER EA, Fohse K, Taks EJM, Moorlag SJCFM, et al The effect of BCG vaccination in the elderly on infectious and non-infectious
immune-mediated diseases.
J Infect. 2024;89:106344. PubMedAbstract available
LIU Y, Yu D, Wang K, Ye Q, et al Global resurgence of pertussis: A perspective from China.
J Infect. 2024;89:106289. PubMedAbstract available
October 2024
WANG H, Zhou Y, Chu L, Chen K, et al Guardian-driven influenza vaccination intentions for children post-COVID-19 in
the 2024-2025 season: The positive spillover effects.
J Infect. 2024;89:106333. PubMed
CHEN X, Meng X, Wu Q, Lim WW, et al Assessment of Neutralizing Antibody Response as a Correlate of Protection against
Symptomatic SARS-CoV-2 Infections after Administration of two doses of the
CoronaVac inactivated COVID-19 Vaccine: A Phase III Randomized Controlled Trial.
J Infect. 2024 Oct 16:106315. doi: 10.1016/j.jinf.2024.106315. PubMedAbstract available
MADSEN AMR, Gehrt L, Schaltz-Buchholzer F, Moller S, et al Evaluating the effect of BCG vaccination for non-specific protection from
infection in senior citizens during the COVID-19 pandemic: a randomised clinical
trial.
J Infect. 2024 Oct 16:106319. doi: 10.1016/j.jinf.2024.106319. PubMedAbstract available
MARCHESE AM, Fries L, Beyhaghi H, Vadivale M, et al Mechanisms and Implications of IgG4 Responses to SARS-CoV-2 and Other Repeatedly
Administered Vaccines.
J Infect. 2024 Oct 15:106317. doi: 10.1016/j.jinf.2024.106317. PubMedAbstract available
MATUSALI G, Cimini E, Mazzotta V, Colavita F, et al Mpox Immune response elicited by MVA-BN vaccine over 12 months of follow-up.
J Infect. 2024;89:106309. PubMed
HANI E, Abdullahi F, Bertran M, Eletu S, et al Trends in invasive Haemophilus influenzae serotype b (Hib) disease in England:
2012/13 to 2022/23.
J Infect. 2024;89:106247. PubMedAbstract available
September 2024
NANQUE LM, Varma A, Thysen SM, Benn CS, et al Effect of a campaign with oral polio vaccine on general health: A
cluster-randomised trial in rural Guinea-Bissau.
J Infect. 2024 Sep 30:106302. doi: 10.1016/j.jinf.2024.106302. PubMedAbstract available
BENNETT C, Hoosain Z, Koen A, Lalloo U, et al Immunogenicity and Safety of SARS-CoV-2 Recombinant Spike Protein Vaccine in
South African People Living With and Without HIV-1 Infection: A Phase 2
Randomised Trial.
J Infect. 2024 Sep 27:106285. doi: 10.1016/j.jinf.2024.106285. PubMedAbstract available
KIRWAN PD, Foulkes S, Munro K, Sparkes D, et al Protection of vaccine boosters and prior infection against mild/asymptomatic and
moderate COVID-19 infection in the UK SIREN healthcare worker cohort: October
2023 to March 2024.
J Infect. 2024 Sep 27:106293. doi: 10.1016/j.jinf.2024.106293. PubMedAbstract available
RABDANO SO, Ruzanova EA, Vertyachikh AE, Teplykh VA, et al N-protein vaccine is effective against COVID-19: phase 3, randomized,
double-blind, placebo-controlled clinical trial.
J Infect. 2024 Sep 26:106288. doi: 10.1016/j.jinf.2024.106288. PubMedAbstract available
MCLEOD C, Dymock, Flanagan KL, Plebanski M, et al The Platform Trial In COVID-19 Priming and BOOsting (PICOBOO): the
immunogenicity, reactogenicity, and safety of different COVID-19 vaccinations
administered as a second booster (fourth dose) in AZD1222 primed individuals aged
50-<70 years old.
J Infect. 2024 Sep 26:106286. doi: 10.1016/j.jinf.2024.106286. PubMedAbstract available
FAUSTINI SE, Hodson J, Birtwistle J, Whitelegg A, et al Comparison of short- and long-term humoral immune responses to pneumococcal
polysaccharide and glycoconjugate vaccines in an HIV-infected population.
J Infect. 2024 Sep 24:106282. doi: 10.1016/j.jinf.2024.106282. PubMedAbstract available
CHRISTENSEN J, Johansen ND, Janstrup KH, Modin D, et al Time of day for vaccination, outcomes, and relative effectiveness of high-dose
vs. standard-dose quadrivalent influenza vaccine: a post-hoc analysis of the
DANFLU-1 randomized clinical trial.
J Infect. 2024 Sep 18:106276. doi: 10.1016/j.jinf.2024.106276. PubMedAbstract available
SKAARUP KG, Lassen MCH, Modin D, Johansen ND, et al Corrigendum to "The relative vaccine effectiveness of high-dose vs standard-dose
influenza vaccines in preventing hospitalization and mortality: A meta-analysis
of evidence from randomized trials" [J Infect 89 (2024) 106187].
J Infect. 2024;89:106270. PubMed
August 2024
AZIZ AB, Sugimoto JD, Hong SL, You YA, et al Indirect effectiveness of a novel SAR-COV-2 vaccine (SCB-2019) in unvaccinated
household contacts in the Philippines: a cluster randomised analysis.
J Infect. 2024 Aug 30:106260. doi: 10.1016/j.jinf.2024.106260. PubMedAbstract available
GRAM MA, Thiesson EM, Pihlstrom N, Perala J, et al Comparative effectiveness of bivalent BA.4-5 or BA.1 mRNA booster vaccines among
immunocompromised individuals across three Nordic countries: A nationwide cohort
study.
J Infect. 2024;89:106261. PubMedAbstract available
FOULKES S, Evans J, Neill C, Bishop J, et al Prevalence and impact of persistent symptoms following SARS-CoV-2 infection among
healthcare workers: a cross-sectional survey in the SIREN cohort.
J Infect. 2024 Aug 28:106259. doi: 10.1016/j.jinf.2024.106259. PubMedAbstract available
FRYER HA, Geers D, Gommers L, Zaeck LM, et al Fourth dose bivalent COVID-19 vaccines outperform monovalent boosters in
eliciting cross-reactive memory B cells to Omicron subvariants.
J Infect. 2024 Aug 8:106246. doi: 10.1016/j.jinf.2024.106246. PubMedAbstract available
MESSINA NL, Pittet LF, McDonald E, Moore C, et al BCG vaccination of healthcare workers for protection against COVID-19: 12-month
outcomes from an international randomised controlled trial.
J Infect. 2024 Aug 8:106245. doi: 10.1016/j.jinf.2024.106245. PubMedAbstract available
FAN C, Yang Y, Zhan S, Sun X, et al The effectiveness and impact of the enterovirus 71 vaccine on the onset of hand,
foot, and mouth disease in children aged =5 years: A 7-year study.
J Infect. 2024;89:106244. PubMed
ALABI A, Kokou K, Mahmoudou S, Kavishna R, et al Replication, safety and immunogenicity of the vectored Ebola vaccine
rVSV-DeltaG-ZEBOV-GP in a sub-Saharan African paediatric population: a randomised
controlled, open-label trial in children aged 1-12 years living in Lambarene,
Gabon.
J Infect. 2024 Aug 7:106237. doi: 10.1016/j.jinf.2024.106237. PubMedAbstract available
QUEK AML, Wang S, Teng O, Shunmuganathan B, et al Hybrid immunity augments cross-variant protection against COVID-19 among
immunocompromised individuals.
J Infect. 2024 Aug 7:106238. doi: 10.1016/j.jinf.2024.106238. PubMedAbstract available
SILVA-COSTA C, Gomes-Silva J, Pinho M, Friaes A, et al Rebound of pediatric invasive pneumococcal disease in Portugal after the COVID-19
pandemic was not associated with significant serotype changes.
J Infect. 2024 Aug 6:106242. doi: 10.1016/j.jinf.2024.106242. PubMedAbstract available
July 2024
ANDREWS N, Osuntoki I, Stowe J, Kirsebom FCM, et al The impact of Covid-19 vaccine spring boosters on Covid-19 hospital admissions in
England 2022/23.
J Infect. 2024 Jul 10:106221. doi: 10.1016/j.jinf.2024.106221. PubMedAbstract available
GRISKAITIS M, Thielemann I, Schonfeld V, Falman A, et al Effectiveness and duration of protection of primary and booster immunisation
against meningococcal serogroup C disease with meningococcal conjugate C and ACWY
vaccines: Systematic review.
J Infect. 2024;89:106228. PubMedAbstract available
WANG B, Mohammed H, Andraweera P, McMillan M, et al Vaccine effectiveness and impact of meningococcal vaccines against gonococcal
infections: A systematic review and meta-analysis.
J Infect. 2024 Jul 8:106225. doi: 10.1016/j.jinf.2024.106225. PubMedAbstract available
June 2024
DU Z, Wang S, Chen R, Shan S, et al Efficacy and safety of respiratory syncytial virus prefusion F protein vaccines
in adults.
J Infect. 2024;89:106211. PubMed
GONG X, Peng L, Wang F, Liu J, et al Repeated Omicron infection dampens immune imprinting from previous vaccination
and induces broad neutralizing antibodies against Omicron sub-variants.
J Infect. 2024;89:106208. PubMedAbstract available
PEREZ-GARCIA C, Sempere J, de Miguel S, Hita S, et al Surveillance of invasive pneumococcal disease in Spain exploring the impact of
the COVID-19 pandemic (2019-2023).
J Infect. 2024;89:106204. PubMedAbstract available
ZHAI K, Dong J, Zeng J, Cheng P, et al Global Antigenic Landscape and Vaccine Recommendation Strategy for Low Pathogenic
Avian Influenza A(H9N2) Viruses.
J Infect. 2024 Jun 18:106199. doi: 10.1016/j.jinf.2024.106199. PubMedAbstract available
AUDRAN R, Karoui O, Donnet L, Soumas V, et al Randomized, double-blind, controlled phase 1 trial of the candidate tuberculosis
vaccine ChAdOx1-85A delivered by aerosol versus intramuscular route.
J Infect. 2024 Jun 17:106205. doi: 10.1016/j.jinf.2024.106205. PubMedAbstract available
MIKOLAJCZYK R, Diexer S, Klee B, Pfrommer L, et al Likelihood of Post-COVID Condition in people with hybrid immunity; data from the
German National Cohort (NAKO).
J Infect. 2024 Jun 17:106206. doi: 10.1016/j.jinf.2024.106206. PubMedAbstract available
PATERNINA-CAICEDO A, Quevedo DS, Rios DS, Moyano D, et al Heterologous and BNT162b2 boosters are more effective than non-mRNA homologous
boosters for Omicron.
J Infect. 2024;88:106165. PubMed
TSANG RSW, Deceuninck G, Meilleur C, Zhou J, et al Temporal variations in the serogroup distribution of invasive meningococcal
disease in Quebec, Canada, due to emerging unique clade of serogroup Y strain
belonging to the Sequence Type-23 clonal complex.
J Infect. 2024;88:106163. PubMedAbstract available
May 2024
SKAARUP KG, Lassen MCH, Modin D, Johansen ND, et al The relative vaccine effectiveness of high-dose vs standard-dose influenza
vaccines in preventing hospitalization and mortality: A meta-analysis of evidence
from randomized trials.
J Infect. 2024;89:106187. PubMedAbstract available
AMANO M, Ichikawa Y, Matsumoto S, Higashi-Kuwata N, et al Neutralization activity of HCWs' sera after Omicron XBB.1.5-adapted monovalent
COVID-19 mRNA vaccination.
J Infect. 2024;89:106179. PubMed
PANG CWK, Vale R, Lao KS, Khan AT, et al Increased Incidence of Invasive Pneumococcal Disease in Hong Kong in 2023.
J Infect. 2024 May 11:106178. doi: 10.1016/j.jinf.2024.106178. PubMedAbstract available
KIRSEBOM FCM, Stowe J, Lopez Bernal J, Allen A, et al Effectiveness of Autumn 2023 COVID-19 vaccination and residual protection of
prior doses against hospitalisation in England, estimated using a test-negative
case-control study.
J Infect. 2024 May 6:106177. doi: 10.1016/j.jinf.2024.106177. PubMedAbstract available
April 2024
MENGYANG G, Yahong H, Qinghong M, Wei S, et al Resurgence and atypical patterns of pertussis in China.
J Infect. 2024;88:106140. PubMed
March 2024
NG M, S D, L W, R B, et al Paediatric meningitis in the conjugate vaccine era and a novel clinical decision
model to predict bacterial aetiology.
J Infect. 2024 Mar 27:106145. doi: 10.1016/j.jinf.2024.106145. PubMedAbstract available
SALMAN M, Rana MS, Usman M, Tahir M, et al Re-emergence of Diphtheria after COVID-19 Pandemic in Pakistan: time to consider
booster vaccination strategies.
J Infect. 2024 Mar 19:106141. doi: 10.1016/j.jinf.2024.106141. PubMed
SUN L, Man Q, Zhang H, Xia S, et al Strong cross immune responses against sarbecoviruses but not merbecoviruses in
SARS-CoV-2 BA.5/BF.7-infected individuals with or without inactivated COVID-19
vaccination.
J Infect. 2024;88:106138. PubMed
FATLY ZA, Betjes MGH, Dik WA, Fouchier RAM, et al Mycophenolate mofetil hampers antibody responses to a broad range of vaccinations
in kidney transplant recipients: results from a randomized controlled study.
J Infect. 2024 Mar 1:106133. doi: 10.1016/j.jinf.2024.106133. PubMedAbstract available
POWELL AA, Dowell AC, Moss P, Ladhani SN, et al Current state of COVID-19 in children: 4 years on.
J Infect. 2024 Mar 1:106134. doi: 10.1016/j.jinf.2024.106134. PubMedAbstract available
February 2024
MEERAUS W, Joy M, Ouwens M, Taylor KS, et al AZD1222 effectiveness against severe COVID-19 in individuals with comorbidity or
frailty: the RAVEN cohort study.
J Infect. 2024 Feb 29:106129. doi: 10.1016/j.jinf.2024.106129. PubMedAbstract available
September 2023
CLARK SA, Campbell H, Ribeiro S, Bertran M, et al Epidemiological and strain characteristics of invasive meningococcal disease
prior to, during and after COVID-19 pandemic restrictions in England.
J Infect. 2023 Sep 7:S0163-4453(23)00504-2. doi: 10.1016/j.jinf.2023. PubMedAbstract available